RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Casdin Capital
C

Casdin Capital portfolio

Casdin Capital has 15 portfolio companies on record at Recent Funding, with 2 investments in the last 12 months.

Type: Venture capital.
Portfolio on Recent Funding: 15.
Deals, last 12 months: 2.
Rounds led: 2 of 15.
Capital in their rounds: $1.58B.
Latest deal: City Therapeutics · Jun 8, 2026.
About this page

It is a venture capital firm based in New York, US, founded in 2012. It led 2 of the 15 rounds it joined. Its most recent investment on record is City Therapeutics's $99.5M Series B+ round in June 2026, alongside Viking Global Investors, Slate Path Capital, ARCH Venture Partners and 6 others. By category, its portfolio leans toward Health and bio (15) and Logistics and mobility (2). It has co-invested with Nextech Invest, ARCH Venture Partners and Rock Springs Capital, most often Nextech Invest (6 rounds).

About Casdin Capital

Firm type: Venture capital.
Headquarters: New York, US.
Founded: 2012.
Stages: Seed, Series A, Series B, Series C.
Sectors: AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Longevity, Medical Devices.
Leads rounds: No.
Portfolio companies: 11.
Exits: 2.
Rounds led: 9.

What Casdin Capital invests in

Casdin Capital recent investments

How Casdin Capital invests

StageDealsCapital in rounds
Series B+ 8 53%$784M
Series A 7 47%$795M
YearDealsCapital in rounds
2020 2 13%$157.5M
2021 4 27%$287M
2022 4 27%$365M
2023 1 7%$270M
2024 1 7%$120M
2025 1 7%$200M
2026 2 13%$179.5M

Casdin Capital portfolio companies

CompanyRound with Casdin CapitalTotal raisedLatest raise
CCity Therapeutics
Health and bio
Series B+ · $99.5M$234.5MAug 8, 2026
Series B+
AApella Technology
Health and bio
Series B+ · $80M$80MJan 8, 2026
Series B+
TTreeline Biosciences
Health and bio
Series A · $200M$461MSep 3, 2025
Series A
IIDRx
Health and bio
Series B+ · $120M$242MAug 8, 2024
Series B+
OOrbital Therapeutics
Health and bio
Series A · $270M$270MAug 3, 2025
Series A
CCharacter Bio
Health and bio
Series A · $18M$111MMar 25, 2025
Series B+
OONI
Health and bio
Series B+ · $75M · lead$75MJan 29, 2022
Series B+
VVerana Health
Health and bio
Series B+ · $150M$202MApr 30, 2026
Series B+
NNomic Bio
Health and bio
Series A · $17M$59MSep 17, 2024
Series B+
EExo Therapeutics
Health and bio
Series B+ · $78M$103MOct 5, 2021
Series B+
TT-Knife
Health and bio
Series B+ · $110M$188MAug 2, 2021
Series B+
FFlare Therapeutics
Health and bio
Series A · $82M$167MJun 30, 2026
Series B+
AA2 Biotherapeutics
Health and bio
Series B+ · $71.5M$270.5MJan 10, 2025
Series B+
MMOMA Therapeutics
Health and bio
Series A · $86M$236MMay 10, 2022
Series B+
TTriGemX Bio
Health and bio
backer$94MOct 1, 2026
round

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 15 rounds on Recent Funding that name Casdin Capital. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Casdin Capital, which is a subset of its real portfolio. API: /api/v1/investors/casdin-capital (get a free API key). More: the most active VC firms and new venture capital funds.